<?xml version="1.0" encoding="UTF-8"?>

<rdf:RDF
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns="http://purl.org/rss/1.0/"
 xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/"
 xmlns:dc="http://purl.org/dc/elements/1.1/"
 xmlns:syn="http://purl.org/rss/1.0/modules/syndication/"
 xmlns:prism="http://purl.org/rss/1.0/modules/prism/"
 xmlns:admin="http://webns.net/mvcb/"
>

<channel rdf:about="http://dtb.bmj.com">
<title>Drug and Therapeutics Bulletin current issue</title>
<link>http://dtb.bmj.com</link>
<description>Drug and Therapeutics Bulletin RSS feed -- current issue</description>
<prism:eIssn>1755-5248</prism:eIssn>
<prism:coverDisplayDate>July 2010</prism:coverDisplayDate>
<prism:publicationName>Drug and Therapeutics Bulletin</prism:publicationName>
<prism:issn>0012-6543</prism:issn>
<items>
 <rdf:Seq>
  <rdf:li rdf:resource="http://dtb.bmj.com/cgi/content/short/48/7/73?rss=1" />
  <rdf:li rdf:resource="http://dtb.bmj.com/cgi/content/short/48/7/74?rss=1" />
  <rdf:li rdf:resource="http://dtb.bmj.com/cgi/content/short/48/7/78?rss=1" />
  <rdf:li rdf:resource="http://dtb.bmj.com/cgi/content/short/48/7/82?rss=1" />
  <rdf:li rdf:resource="http://dtb.bmj.com/cgi/content/short/48/7/84?rss=1" />
 </rdf:Seq>
</items>
<image rdf:resource="http://hwmaint.dtb.bmj.com/icons/banner/title.gif" />
</channel>

<image rdf:about="http://hwmaint.dtb.bmj.com/icons/banner/title.gif">
<title>Drug and Therapeutics Bulletin</title>
<url>http://hwmaint.dtb.bmj.com/icons/banner/title.gif</url>
<link>http://dtb.bmj.com</link>
</image>

<item rdf:about="http://dtb.bmj.com/cgi/content/short/48/7/73?rss=1">
<title><![CDATA[Money, money, money]]></title>
<link>http://dtb.bmj.com/cgi/content/short/48/7/73?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[]]></dc:creator>
<dc:date>Wed, 14 Jul 2010 09:52:23 PDT</dc:date>
<dc:subject><![CDATA[Cardiovascular Medicine, Cardiovascular system, Public health, General practice / family medicine, Epidemiology]]></dc:subject>
<dc:identifier>info:doi/10.1136/dtb.2010.05.0036</dc:identifier>
<dc:title><![CDATA[Money, money, money]]></dc:title>
<dc:publisher>British Medical Journal Publishing Group</dc:publisher>
<prism:number>7</prism:number>
<prism:volume>48</prism:volume>
<prism:endingPage>73</prism:endingPage>
<prism:publicationDate>2010-07-01</prism:publicationDate>
<prism:startingPage>73</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://dtb.bmj.com/cgi/content/short/48/7/74?rss=1">
<title><![CDATA[Preventing exacerbations in COPD]]></title>
<link>http://dtb.bmj.com/cgi/content/short/48/7/74?rss=1</link>
<description><![CDATA[
<p>Acute exacerbations of chronic obstructive pulmonary disease (COPD) are associated with significant morbidity and mortality. Patients with frequent exacerbations have high levels of anxiety and depression, significantly impaired health status and faster disease progression.<cross-ref type="bib" refid="b1">1</cross-ref><sup>,</sup><cross-ref type="bib" refid="b2">2</cross-ref> Exacerbations are also the most common cause of emergency respiratory admissions to UK hospitals<cross-ref type="bib" refid="b3">3</cross-ref> and are costly to health services.<cross-ref type="bib" refid="b2">2</cross-ref> Here we assess whether and how drug and non-drug interventions can help in preventing exacerbations. </p>
]]></description>
<dc:creator><![CDATA[]]></dc:creator>
<dc:date>Wed, 14 Jul 2010 09:52:23 PDT</dc:date>
<dc:subject><![CDATA[Emergency medicine, Public health, Epidemiology]]></dc:subject>
<dc:identifier>info:doi/10.1136/dtb.2010.05.0037</dc:identifier>
<dc:title><![CDATA[Preventing exacerbations in COPD]]></dc:title>
<dc:publisher>British Medical Journal Publishing Group</dc:publisher>
<prism:number>7</prism:number>
<prism:volume>48</prism:volume>
<prism:endingPage>77</prism:endingPage>
<prism:publicationDate>2010-07-01</prism:publicationDate>
<prism:startingPage>74</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://dtb.bmj.com/cgi/content/short/48/7/78?rss=1">
<title><![CDATA[{blacktriangledown}Febuxostat for gout]]></title>
<link>http://dtb.bmj.com/cgi/content/short/48/7/78?rss=1</link>
<description><![CDATA[
<p>Around 1.4% of the UK population have gout, the prevalence of which increases with age to around 3% in women and 7% in men aged over 75 years.<cross-ref type="bib" refid="b1">1</cross-ref><cross-ref type="bib" refid="b2">&ndash;</cross-ref><cross-ref type="bib" refid="b3">3</cross-ref> Acute gout is intensely painful and can reduce patients&rsquo; quality of life.<cross-ref type="bib" refid="b2">2</cross-ref><sup>,</sup><cross-ref type="bib" refid="b3">3</cross-ref> It occurs when the serum uric acid concentration (SUA) rises (hyperuricaemia) and persists above the solubility threshold of monosodium urate (400&micro;mol/L [6.8mg/dL]), leading to urate crystal formation that causes arthritis, gouty tophi (nodules) in subcutaneous tissues and renal calculi.<cross-ref type="bib" refid="b3">3</cross-ref><cross-ref type="bib" refid="b4">&ndash;</cross-ref><cross-ref type="bib" refid="b5">5</cross-ref> The mainstay of treatment for chronic gout is allopurinol, which inhibits xanthine oxidase (an enzyme involved in the production of uric acid in the body). However, this drug has to be stopped in a minority of patients due to rashes or hypersensitivity.<cross-ref type="bib" refid="b6">6</cross-ref> Febuxostat (Adenuric &ndash; Menarini/Ipsen), another xanthine oxidase inhibitor, is a newly licensed treatment for chronic hyperuricaemia in conditions where urate deposition has occurred.<cross-ref type="bib" refid="b7">7</cross-ref> Here we consider its place for patients with gout. </p>
]]></description>
<dc:creator><![CDATA[]]></dc:creator>
<dc:date>Wed, 14 Jul 2010 09:52:23 PDT</dc:date>
<dc:subject><![CDATA[Urinary and genital tract disorders, Malignant disease and immunosuppression, Haematology (drugs and medicines), Nutrition, Musculoskeletal and joint disorders, Urology, Genetics, Immunology (including allergy), Renal medicine, Rheumatology]]></dc:subject>
<dc:identifier>info:doi/10.1136/dtb.2010.02.0017</dc:identifier>
<dc:title><![CDATA[{blacktriangledown}Febuxostat for gout]]></dc:title>
<dc:publisher>British Medical Journal Publishing Group</dc:publisher>
<prism:number>7</prism:number>
<prism:volume>48</prism:volume>
<prism:endingPage>82</prism:endingPage>
<prism:publicationDate>2010-07-01</prism:publicationDate>
<prism:startingPage>78</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://dtb.bmj.com/cgi/content/short/48/7/82?rss=1">
<title><![CDATA[How medical devices are regulated in the UK]]></title>
<link>http://dtb.bmj.com/cgi/content/short/48/7/82?rss=1</link>
<description><![CDATA[
<p>Excluding medicines, most other healthcare products are medical devices.<cross-ref type="bib" refid="b1">1</cross-ref> It is estimated that around 38 million people in the UK "have contact with" a medical device every day,<cross-ref type="bib" refid="b2">2</cross-ref> and there are more than 80,000 different devices on the UK market.<cross-ref type="bib" refid="b3">3</cross-ref> Examples include scanners, pacemakers, infusion equipment, condoms, pregnancy test kits, beds, wheelchairs and dressings.<cross-ref type="bib" refid="b4">4</cross-ref> All but the very lowest risk devices must conform to specific European Directives. Here we look at the procedures now involved in the regulation of medical devices in the UK. </p>
]]></description>
<dc:creator><![CDATA[]]></dc:creator>
<dc:date>Wed, 14 Jul 2010 09:52:23 PDT</dc:date>
<dc:subject><![CDATA[Public health]]></dc:subject>
<dc:identifier>info:doi/10.1136/dtb.2020.03.0023</dc:identifier>
<dc:title><![CDATA[How medical devices are regulated in the UK]]></dc:title>
<dc:publisher>British Medical Journal Publishing Group</dc:publisher>
<prism:number>7</prism:number>
<prism:volume>48</prism:volume>
<prism:endingPage>84</prism:endingPage>
<prism:publicationDate>2010-07-01</prism:publicationDate>
<prism:startingPage>82</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://dtb.bmj.com/cgi/content/short/48/7/84?rss=1">
<title><![CDATA[{blacktriangledown}Liraglutide for type 2 diabetes - new data]]></title>
<link>http://dtb.bmj.com/cgi/content/short/48/7/84?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[]]></dc:creator>
<dc:date>Wed, 14 Jul 2010 09:52:23 PDT</dc:date>
<dc:identifier>info:doi/10.1136/dtb.2010.01.0006corr1</dc:identifier>
<dc:title><![CDATA[{blacktriangledown}Liraglutide for type 2 diabetes - new data]]></dc:title>
<dc:publisher>British Medical Journal Publishing Group</dc:publisher>
<prism:number>7</prism:number>
<prism:volume>48</prism:volume>
<prism:endingPage>84</prism:endingPage>
<prism:publicationDate>2010-07-01</prism:publicationDate>
<prism:startingPage>84</prism:startingPage>
<prism:section>Correction</prism:section>
</item>

</rdf:RDF>